FDA Panel To Discuss “Breakpoint” Changes For Systemic Antibiotics
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-Infective Drugs Advisory Committee will meet Oct. 17 to discuss whether and when it is appropriate to base susceptibility test interpretive criteria on the highest or lowest approved dose of a drug, or whether labeling should reflect breakpoints specific to each approved dosing regimen and indication.
You may also be interested in...
Cubist Tedizolid Advisory Cmte. Review Will Gauge FDA’s Mood On Antibiotic “Breakpoints”
Cubist’s second-generation oxazolidineone is set for an FDA advisory committee review in March.
FDA Panel Sees Role For PK/PD Modeling In Revising Antibiotic “Breakpoints”
In certain circumstances it may be appropriate to change the criteria for determining when a pathogen is susceptible to a drug and recommended doses for systemic antibacterials absent clinical outcomes data, Anti-Infective Drugs Advisory Committee says.
Drug Makers Face Higher Relabeling Burden For Antibacterial Resistance Info
FDA plans to issue a yearly update on the susceptibility of bacteria to treatment by individual antibiotics and has drafted guidance that calls on drug makers to revise labeling for systemic antibacterial products accordingly